Further proof of the effectiveness of luteolin came from the association with S1P, its agonist and key factor in the proliferation of tumor stem cells, the single administration of which caused an increase in proliferation of about 40%, which was, however, inhibited by the concomitant administration of luteolin (Figure 3C). This evidence concerns the gene MBTPS1 and neoplasm.